Effect of PCNA inhibitors on the temporal cascade of viral protein expression. by Jessica E. Packard (16641690)

Bar graphs showing the concentrations of different redox markers examined. by Rege Anna Márton (18536676)

Bar graphs showing the concentrations of different inflammatory markers examined. by Rege Anna Márton (18536676)

Intradermal testing. by Ana Leda F. Longhini (226617)

DataSheet_2_The predictive value of free thyroxine combined with tubular atrophy/interstitial fibrosis for poor prognosis in patients with IgA nephropathy.csv by Bixia Yang (18550324)

“…The renal composite outcomes were defined as: (1) ESRD, defined as eGFR < 15 ml/(min·1.73 m²) or initiation of renal replacement therapy (hemodialysis, peritoneal dialysis, renal transplantation); (2) serum creatinine doubled from baseline; (3) eGFR decreased by more than 50% from baseline. The predictive value was determined by the area under the curve (AUC). …”

DataSheet_1_The predictive value of free thyroxine combined with tubular atrophy/interstitial fibrosis for poor prognosis in patients with IgA nephropathy.docx by Bixia Yang (18550324)

“…The renal composite outcomes were defined as: (1) ESRD, defined as eGFR < 15 ml/(min·1.73 m²) or initiation of renal replacement therapy (hemodialysis, peritoneal dialysis, renal transplantation); (2) serum creatinine doubled from baseline; (3) eGFR decreased by more than 50% from baseline. The predictive value was determined by the area under the curve (AUC). …”

ASYN biochemical state. by Diana F. Lázaro (659832)

Fold change in <i>D</i>. <i>melanogaster</i> manganese-dependent superoxide dismutase (Mn-SOD) expression in response to UVC radiation. by Mohamed Lotfy (18599184)

Basal medium with autologous plasma (AP) or autologous platelet lysate (APL) results in loss of cell surface marker phenotype and impaired growth respectively. by Ana Leda F. Longhini (226617)

Immunofluorescence for autophagic proteins following DMBA treatment. by Evie H. Carchman (3195855)

“…(D) With 10 weeks of DMBA treatment, there is significant accumulation of p62 expression and an increase in punctate LC3β indicating autophagic induction without degradation of autophagy-specific substrate p62. (E) At 15 weeks of DMBA treatment, the time of development of high-grade dysplasia, p62 levels begin to decrease with continued evidence of punctate LC3β indicating autophagic induction with the ability to degrade p62. …”

Fig 8 - by Rashida Nayeem (11851764)

The use of NSAF to compare protein abundance in replicate viral aniPOND data sets and between different infection conditions. by Jessica E. Packard (16641690)

“…Red data points represent proteins that decreased at least 4-fold and green data points increased at least 4-fold in the presence of either PCNA-I1 or T2AA.…”

Data Sheet 7_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 6_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 1_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 3_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 8_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 4_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 5_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 2_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”